Reviva Pharmaceuticals to Host Key Opinion Leader Webinar on Brilaroxazine for Schizophrenia and Other Neuropsychiatric Disorders

Apr 26, 2022 | Press Releases

Virtual event on Tuesday, May 3rd at 10:00 AM ET An overview of unmet medical needs and therapeutic opportunities in schizophrenia and major neuropsychiatric disorders will be discussed CUPERTINO, Calif., April 26, 2022 — Reviva Pharmaceuticals Holdings, Inc....

Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Mar 24, 2022 | Press Releases

CUPERTINO, Calif., March 24, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. to Participate at the Maxim Virtual Growth Conference

Mar 22, 2022 | Press Releases

CUPERTINO, Calif., March 22, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences

Mar 18, 2022 | Press Releases

– 5th Annual Neuroscience Innovation Forum – – BIO-Europe Spring® 2022 – CUPERTINO, Calif., March 18, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...

Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights

Mar 15, 2022 | Press Releases

– Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 – $29.7 Million in Cash as of December 31, 2021 – CUPERTINO, Calif., March 15, 2022 — Reviva Pharmaceuticals Holdings,...